

Anti-BrdU [IIB5]

Catalog No.	Description	
AM984-5M	6 ml of Ready-to-Use Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system	
AM984-10M	10 ml of Ready-to-Use Antibody in a barcode labeled vial for use with BioGenex Super Sensitive TM Detection Systems and i6000 TM Automated Staining Systems	
MU984-UC	1 ml of Concentrated Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system	
MU984-5UC	0.5 ml of Concentrated Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system	
AX984-YCD	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx [®] Elite Staining System, 160 tests	
AX984-50D	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx [®] Elite Staining System, 50 tests	
AX984-4M	Ready-to-Use Antibody in Barcode labeled vial for use on the NanoVIP [®] Staining System, 50 tests	

Clone	Species	Ig Class
IIB5	Mouse	IgG1

Intended Use

For Research Use. This antibody is designed for the specific localization of human BrdU in formalin-fixed, paraffinembedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

Summary and Explanation

BrdU or bromodeoxyuridine (5-Bromo-2'-deoxyuridin) is a synthetic nucleoside that is analogous to thymidine. Due to its analogy to thymidine, BrdU can replace the thymidine and can be incorporated into newly synthesized DNA during the S-phase of the cell cycle. This makes BrdU a very important tool in detecting proliferating cells. BrdU is neither radioactive nor myelotoxic at labeling concentrations. This makes it a very useful tool in monitoring the proliferation of cancer cells invivo.

Storage and Handling

Store at 2-8°C. Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

Principles of the Procedure

Antigen detection by immunohistochemistry (<u>IHC</u>) is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The <u>primary</u> <u>antibody</u> may be used in IHC using manual techniques or BioGenex Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

Reagents Provided

Mouse Monoclonal Antibody human BrdU is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide

Dilution of Primary Antibody

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution.

BioGenex concentrated antibodies must be diluted in accordance with the recommended protocol when used with the recommended BioGenex Detection System.

Recommended Protocol

Refer to the following table for conditions specifically recommended for this antibody. Refer to the BioGenex website for guidance on specific staining protocols or other requirements.

Parameter	BioGenex Recommendations	
Control Tissue	Colon tissue as available with Biogenex FB-984M* & FG- 984M*	
Recommended Dilution for Concentrated Antibody	1:20- 40 in HK941	
Recommended Pretreatment (Manual/i6000)**	EZ-AR2 (HK522-XAK) (2 times)	
Recommended Pretreatment (Xmatrx & NanoVIP)	EZ-AR2 Elegance (HX032- YCD & HX046-08XN)	
Antibody Incubation (Manual/i6000)	30-60 Min at RT	
Antibody Incubation (Xmatrx & NanoVIP)	45-60 Min at 25°C	
Detection System for Manual, Xmatrx, NanoVIP & i6000 systems***	Use BioGenex Two-Step OR One-Step Super Sensitive [™] Polymer-HRP IHC Detection System/DAB; see p. 2 for more information	

*FB: positive control micro chamber slides, FG: positive control microscopic slides. Xmatrx & NanoVIP requires micro chamber slides.

Category	Antibodies	Revision No.	F
Document No.	932-984M-EN	Release Date	23-Jan-2023



Pretreatment times will vary based on individual microwave power. *For automation systems (Xmatrx-Elite, NanoVIP & i6000 Diagnostics), refer to the factory protocols provided with the instrument.

Detection	Two-Step	One-Step	Link and
System	HRP Kit	HRP Kit	Label Kit
Manual	QD440-XAKEN (1000 Test) QD430-XAKEN (1000 Test)	QD630-XAKEN (1000 Test)	QP300- XAKE (1000 Test)
Manual	QD420-YIKEN (500 Test) QD400-60KEN (60 Test)	QD620-XAKEN (500 Test)	QP900- 9LE (500 Test)
Xmatrx - Automation	QD550-YCDEN (200 Test)	QD610-YADEN (200 Test)	N/A
NanoVIP- Automation	QD551-YCDEN (100 Test)	QD611-YADEN (100 Test)	N/A
i6000 - Automation	QD410-YAXEN (200 Test)	QD610-YAXEN (200 Test)	N/A
For more information, visit <u>www.biogenex.com</u> .			

Precautions

This product contains sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations, but proper handling protocols should be observed. For more information, a Safety Data Sheet (SDS) for sodium azide is available upon request. Dispose of unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water.

Quality Control

Refer to BioGenex detection system documents for guidance on general quality control procedures.

Troubleshooting

Refer to the troubleshooting section in the documentation for BioGenex Detection Systems (or equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149 or <u>support@biogenex.com</u> or your local distributor to report unusual staining.

Expected Results


This antibody stains nucleus in positive cells in formalin-fixed, paraffin embedded tissue sections. An example image of a tissue section stained with this antibody can be found on the product page on the BioGenex website. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medically-established

diagnostic product or procedure. Limitations of the Procedure

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems. Improper counterstaining and mounting may compromise the interpretation of results.

Bibliography

- Lehner B, Sandner B, Marschallinger J, et al. The dark side of BrdU in neural stem cell biology: detrimental effects on cell cycle, differentiation and survival. Cell Tissue Res. 2011 Sep; 345(3):313-28
- Russo A, Gianni L, Kinsella TJ, et al. Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors. Cancer Res. 1984 Apr; 44(4):1702-5.
- Fujimaki T, Matsutani M, Nakamura O, et al. Correlation between bromodeoxyuridine-labeling indices and patient prognosis in cerebral astrocytic tumors of adults. Cancer. 1991 Mar 15; 67(6):1629-34.
- 4. Hoshino T, Nagashima T, Murovic J, et al. Cell kinetic studies of in situ human brain tumors with bromodeoxyuridine. Cytometry. 1985 Nov; 6(6):627-32.



© 2020, BioGenex Laboratories. All rights reserved.

Category	Antibodies	Revision No.	F
Document No.	932-984M-EN	Release Date	23-Jan-2023